Analytical Data
-
Gene name
DDAH2
- Application
-
Alternative Names
DDAH2；DDAH；G6A；NG30；Putative hydrolase DDAH2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95865
-
Expression Region
1-285aa
-
AA Sequence
MGTPGEGLGRCSHALIRGVPESLASGEGAGAGLPALDLAKAQREHGVLGGKLRQRLGLQLLELPPEESLPLGPLLGDTAVIQGDTALITRPWSPARRPEVDGVRKALQDLGLRIVEIGDENATLDGTDVLFTGREFFVGLSKWTNHRGAEIVADTFRDFAVSTVPVSGPSHLRGLCGMGGPRTVVAGSSDAAQKAVRAMAVLTDHPYASLTLPDDAAADCLFLRPGLPGVPPFLLHRGGGDLPNSQEALQKLSDVTLVPVSCSELEKAGAGLSSLCLVLSTRPHS
-
Molecular Weight
61.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DDAH2, or Dimethylarginine Dimethylaminohydrolase 2, is an important enzyme that plays a key role in the regulation of nitric oxide synthesis by degrading asymmetrical dimethylarginine (ADMA), a known inhibitor of nitric oxide synthase. The imbalance of ADMA levels is implicated in various cardiovascular diseases, neurodegenerative disorders, and metabolic syndromes. Due to its significant biological functions, DDAH2 presents a promising target for therapeutic intervention. Research has focused on understanding the molecular mechanisms governing DDAH2 expression and activity, as well as exploring its potential as a biomarker for disease diagnosis and prognosis. Furthermore, the recombinant expression of DDAH2 allows for detailed biochemical studies, including enzyme kinetics and structural characterization, which can provide insights into its functionality and regulation. The development of DDAH2-based therapies could lead to innovative treatment strategies for conditions associated with impaired nitric oxide signaling, highlighting the enzyme's relevance in both basic science and clinical applications.
